Bliss GVS Pharma Stock Under Scrutiny Following WHO Inspection Closure Report
Bliss GVS Pharma Shares in Focus Following WHO Inspection Clearance
Bliss GVS Pharma shares will remain in the spotlight on June 3, 2026, following the receipt of an inspection closure report from the World Health Organization (WHO) in Geneva for its manufacturing facility in Palghar, Maharashtra.
The WHO report confirmed that the facility complies with the Good Manufacturing Practices (GMP) standards prescribed by the WHO, reaffirming the plant's adherence to global quality and manufacturing benchmarks.
In the previous trading session, the company's shares closed at Rs 434.75, representing a gain of Rs 32.75, or 8.15 percent.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Key Statistics
| Date | 52-Week High | 52-Week Low |
|---|---|---|
| 02 June, 2026 | Rs 442.20 | - |
| 10 November, 2025 | - | Rs 118.35 |
The share touched a 52-week high of Rs 442.20 and a 52-week low of Rs 118.35 on 02 June, 2026, and 10 November, 2025, respectively. Currently, the stock is trading 1.68 percent below its 52-week high and 267.34 percent above its 52-week low.
The company's market capitalisation stands at Rs 4,599.18 crore.
Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Investor Takeaway
Investors should monitor the stock's performance following the WHO inspection closure report.
More in Market
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Indian Stocks to Watch: BHEL, Agarwal Industrial, JBM Auto, Rajesh Exports, Indian Energy Exchange, Lenskart Solutions in Market Focus on June 4.
